Consensus Relay Therapeutics, Inc.

Equities

RLAY

US75943R1023

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
7.53 ^USD	-0.40%		+10.82%	-31.61%

May. 14	Transcript : Relay Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 01:40 PM
May. 10	Barclays Upgrades Relay Therapeutics to Overweight From Equalweight With $15 Price Target	MT

Evolution of the average Target Price on Relay Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

4b2a974e.54mNiO-PhcBA6WzhYM3xn_IqXVIokbZ_Xwv2KGJhLzI.kb_M-b3YxPcDrAW1JoOry4ccGQRJpPcYFkKyUk8EGV-z5rvEjP7zpyq6Cw~a358933dc16c57f4bac37075b081f6ec

Analyst Recommendations on Relay Therapeutics, Inc.

Barclays Upgrades Relay Therapeutics to Overweight From Equalweight With $15 Price Target	May. 10	MT
Oppenheimer Adjusts Relay Therapeutics Price Target to $25 From $33, Maintains Outperform Rating	May. 06	MT
HC Wainwright Adjusts Price Target on Relay Therapeutics to $17 From $19, Keeps Buy Rating	Dec. 11	MT
HC Wainwright Lowers Price Target on Relay Therapeutics to $19 From $33, Maintains Buy Rating	Nov. 08	MT
HC Wainwright Adjusts Price Target on Relay Therapeutics to $30 From $32, Keeps Buy Rating	23-08-17	MT
Berenberg Bank Adjusts Relay Therapeutics Price Target to $28 From $40, Maintains Buy Rating	23-04-26	MT
Jefferies Upgrades Relay Therapeutics to Hold From Underperform, Adjusts Price Target to $12.50 From $16	23-04-20	MT
Stifel Adjusts Price Target on Relay Therapeutics to $34 From $38, Maintains Buy Rating	23-04-20	MT
JPMorgan Adjusts Price Target on Relay Therapeutics to $29 From $42, Keeps Overweight Rating	23-04-19	MT
Raymond James Upgrade Relay Therapeutics to Strong Buy Rating From Outperform, Price Target is $29	23-04-19	MT
Barclays Cuts Price Target on Relay Therapeutics to $15 From $23, Keeps Equalweight Rating	23-04-19	MT
Raymond James Initiates Relay Therapeutics at Outperform With $29 Price Target	23-04-13	MT
JPMorgan Adjusts Price Target on Relay Therapeutics to $42 From $45, Maintains Overweight Rating	23-04-05	MT
HC Wainwright Adjusts Price Target on Relay Therapeutics to $46 From $43, Maintains Buy Rating	23-03-07	MT
Berenberg Bank Adjusts Relay Therapeutics' Price Target to $40 From $45, Maintains Buy Rating	23-03-01	MT
Oppenheimer Initiates Coverage on Relay Therapeutics With Outperform Rating, $33 Price Target	23-02-03	MT
JMP Securities Adjusts Price Target on Relay Therapeutics to $28 From $38, Maintains Market Outperform Rating	23-01-19	MT
HC Wainwright Adjusts Price Target on Relay Therapeutics to $43 From $50, Maintains Buy Rating	22-11-07	MT
Barclays Starts Relay Therapeutics at Equalweight With $23 Price Target	22-09-30	MT
JMP Securities Adjusts Price Target on Relay Therapeutics to $38 From $35, Maintains Market Outperform Rating	22-09-14	MT
HC Wainwright Adjusts Relay Therapeutics' Price Target to $50 from $46, Maintains Buy Rating	22-09-12	MT
Stifel Starts Relay Therapeutics at Buy With $40 Price Target	22-09-02	MT
HC Wainwright Trims Price Target on Relay Therapeutics to $46 From $47, Reiterates Buy Rating	22-08-09	MT
Goldman Sachs Adjusts Price Target for Relay Therapeutics to $43 From $42, Maintains Buy Rating	22-08-05	MT
Jefferies Initiates Relay Therapeutics at Underperform With $13 Price Target	22-06-06	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.53 USD

Average target price

21.96 USD

Spread / Average Target

+191.68%

High Price Target

29 USD

Spread / Highest target

+285.13%

Low Price Target

10.6 USD

Spread / Lowest Target

+40.77%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Relay Therapeutics, Inc.

Barclays
Oppenheimer
HC Wainwright
Berenberg Bank
Stifel Nicolaus
Jefferies & Co.
JPMorgan Chase
Raymond James
JMP Securities
Stifel FirstEnergy
Goldman Sachs
Guggenheim
BofA Securities
J.P. Morgan Chase

Ratings for Relay Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar